Cell Reports Medicine· Siyuan Luan, Jun Sun, Yijun Dong, Jin Tan, Xin Xiao, Jintong Zhang, Xiaokun Li, Jianfeng Zhou, Pinhao Fang, Haowen Zhang, Shangwei Sun, Zewen Wang, Jian Wang, Tara SR. Chen, Xiaoting Chen, Yushang Yang, Haopeng Yu, Hui Yang, Longqi Chen, Xiaoxi Zeng, An-Yuan Guo, Junjun Ding, Yong Yuan·· 18 小时前AI 评分43
靶向致癌性 SOX2 凝聚体抑制鳞状细胞癌进展
Targeting oncogenic SOX2 condensates suppresses squamous cell carcinoma progression
AI 导读
Luan 等发现，伊沙佐米（ixazomib）以 HSP70 依赖方式选择性破坏 SOX2 凝聚体，抑制鳞状细胞癌进展。SOX2 凝聚体通过调控染色质组织和癌基因表达促进肿瘤进展，这一发现提示了生物标志物指导的治疗策略；该药已获 FDA 批准，但原文未说明获批适应症。
来源：Cell Reports Medicine · cell.com